OpenAI researchers plan to establish an AI pharmaceutical company and are currently in discussions for financing at a valuation of $2 billion.

OpenAI researcher Miles Wang is about to leave the ChatGPT developer and instead start an AI company focused on drug research and development. Several other OpenAI researchers are expected to join this new project. Currently, Miles Wang is in negotiations for about $200 million in funding at a valuation of $2 billion.